Itraconazole versus Pentamidine for the treatment of Tegumentary Leishmaniasis caused by Leishmania guyanensis in Amazonas - randomized controlled clinical trial

Fund. de Medicina Tropical Dr Heitor Vieira Dourado0 个研究点开始时间: 2020年2月11日最近更新: 2023年5月29日

适应症

试验速览

暂无简介。

•Patients with Ulcerated Cutaneous Leishmaniasis, not previously treated; diagnosed through at least one of the following tests: direct examinations of the lesion, biopsy of the lesion, culture or polimerase chain reactions (PCR) positives to Leishmania guyanensis; age of 18-65 years old; both genders; presenting at least 1 to 3 ulcerated lesions, in any localization; lesion diameter between 1-5 cm; clinical evolution not inferior to 1 month and not superior to 3 months.

•Evidence of severe underlying disease (heart, kidney, liver, lung) or malignant disease; immunodeficient or HIV-infected patients; severe protein and / or caloric malnutrition; any active and uncontrolled infectious disease, such as tuberculosis, leprosy, systemic fungal disease (histoplasmosis, paracoccidioidomycosis); pregnant or nursing women; history of previous treatment for leishmaniasis; inability or willingness to provide informed consent (patient and / or / legal representative); lack of availability for visits or to comply with study procedures; patients participating in another ongoing clinical study.

发起方

Fund. de Medicina Tropical Dr Heitor Vieira Dourado